首页> 外文OA文献 >Application of Membrane Separation Processes in the Pharmaceutical Industry – A Study of Process Development for Overcoming Membrane Limitations
【2h】

Application of Membrane Separation Processes in the Pharmaceutical Industry – A Study of Process Development for Overcoming Membrane Limitations

机译:膜分离工艺在制药工业中的应用 - 克服膜限制的工艺开发研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The prevalent business model in the pharmaceutical industry requires rapid and robust process development and flexible manufacturing processes. This work reports the attempts to develop structured procedures for membrane process development to meet these requirements.udThe Donnan Steric Pore Model, in conjunction with a computational molecular dynamics programme, was evaluated as tool for membrane performance predictions to circumvent the need for tedious membrane screening experiments. However, the computational effort required was too onerous, making experimentation more efficient than computational method at this stage.udProcess chemistry manipulation enabled the use of otherwise incompatible membranes for separation and reduced the time needed for membrane scoping. Firstly, through pH manipulation to selectively increase electrostatic sieving, the permeation selectivity of a membrane to 2 different solutes was changed. Secondly, a structured procedure for polyalkylation of an ‘anchor’ molecule to increase the steric hindrance of an organocatalyst was used to enable the total retention of the catalyst so that a single stage membrane recycling strategy for the catalyst could be enacted.udPublished membrane processes were analysed and found to lack robustness and to be too sensitive to slight deviations in membrane performance. Hence new membrane processes were devised to address these challenges. Firstly, a membrane cascade process was used to enhance the rejection of an active pharmaceutical ingredient (API) over the single pass membrane rejection. This cascade process was then used for concurrent API concentration and solvent recovery. Secondly, a permeable stripping cascade configuration was used for the removal of an excess reagent from an API to enable the excess loading of the reagent to increase the yield of the API. The membrane cascades benefited from enhanced reliability, increased productivity and improved robustness.
机译:制药行业中普遍存在的业务模型要求快速而稳健的过程开发和灵活的制造过程。这项工作报告了为满足这些要求而开发用于膜工艺开发的结构化程序的尝试。 ud将Donnan Steric孔模型与计算分子动力学程序结合起来,作为预测膜性能的工具进行了评估,从而避免了繁琐的膜筛选的需求实验。但是,所需的计算工作量太繁重,使该阶段的实验比计算方法更有效。 ud化学过程的化学操作使得能够使用其他不相容的膜进行分离,并减少了膜定型所需的时间。首先,通过控制pH以选择性地增加静电筛分,改变了膜对2种不同溶质的渗透选择性。其次,使用结构化程序对“锚定”分子进行聚烷基化以增加有机催化剂的空间位阻,以实现催化剂的完全保留,从而可以制定用于催化剂的单级膜回收策略。经分析发现缺乏鲁棒性,并且对膜性能的轻微偏差过于敏感。因此,设计了新的膜工艺来应对这些挑战。首先,采用膜级联法来增强活性药物成分(API)的排斥率,而不是单次通过膜的排斥率。然后将此级联过程用于同时进行API浓缩和溶剂回收。其次,使用渗透汽提级联构型从API中去除过量的试剂,以使试剂的过量负载能够增加API的产率。膜级联受益于更高的可靠性,更高的生产率和更高的耐用性。

著录项

  • 作者

    Siew Weiming Eugene;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号